Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | PBK | Q96KB5 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.40 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | PDE6D | O43924 | 1/20 | 0.38 |
| ▸ | PDE6A | P16499 | 1/20 | 0.38 |
| ▸ | PDE6G | P18545 | 1/20 | 0.38 |
| ▸ | PDE6B | P35913 | 1/20 | 0.38 |
| ▸ | PDE6C | P51160 | 1/20 | 0.38 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29923702 | 0.85 | EGLN1 (0.46) | EGLN1CNR1CNR2PARP1SSTR1 | |
| SCHEMBL29923590 | 0.85 | EGLN1 (0.42) | EGLN1CNR1CNR2LMNATP53 | |
| SCHEMBL24916011 | 0.80 | PBK (0.38) | CNR2PBK | |
| SCHEMBL29923860 | 0.80 | PARP1 (0.49) | EGLN1PARP1 | |
| SCHEMBL29923816 | 0.79 | EGLN1 (0.54) | EGLN1PARP1 | |
| SCHEMBL29923336 | 0.78 | EGLN1 (0.52) | EGLN1LMNA | |
| SCHEMBL29923768 | 0.77 | EGLN1 (0.52) | EGLN1 | |
| SCHEMBL29923470 | 0.76 | EGLN1 (0.51) | EGLN1PARP1 | |
| SCHEMBL29923343 | 0.75 | PARP1 (0.52) | EGLN1LMNAPARP1 | |
| SCHEMBL29923798 | 0.74 | NPC1 (0.52) | EGLN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230026466-A1 | WDR5 INHIBITORS AND MODULATORS | VANDERBILT UNIVERSITY | 2023-01-26 | — | — | US | disclosed |
| EP-4055013-A1 | WDR5 INHIBITORS AND MODULATORS | Vanderbilt University (US) | 2022-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026466-A1 | WDR5 INHIBITORS AND MODULATORS | WDR5, WDR1, WDR3 | EGLN1 1068/4885CNR1 3395/4885CNR2 3646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.